癌症患者伴与不伴静脉血栓栓塞事件的生物标志物特征:CASSINI研究的子研究
该研究利用CASSINI试验中62例发生静脉血栓栓塞(VTE)的癌症患者与按年龄、性别、癌症类型、肿瘤分期和Khorana评分匹配的62例对照,分析基线280种生物标志物。VTE患者中SDF-1、TSH和单核细胞趋化蛋白4降低,生长激素和IL-1R1升高;生存者与死亡者之间ST2、IL-8和C反应蛋白显著不同。回归分析还识别出SDF-1和TSH降低,通路分析显示细胞因子和趋化因子活性富集。
要点
- CASSINI子研究匹配62例VTE患者与62例对照,分析基线280种生物标志物。
- VTE患者中SDF-1、TSH和单核细胞趋化蛋白4降低,生长激素和IL-1R1升高。
- 回归分析识别SDF-1和TSH降低,IL-1R1、SDF-1和GH为VTE或死亡最强预测因子。
核心结论
- 分析突显止血与炎症过程的相互作用,并识别癌症相关VTE的候选生物标志物。
- 前瞻性研究将确定这些生物标志物的临床相关性。
研究设计与样本
- CASSINI研究的子研究,利用其血液样本比较伴与不伴VTE患者的生物标志物水平。
- CASSINI研究6个月期间62例发生VTE者为病例,按年龄、性别、癌症类型、肿瘤分期和Khorana评分匹配62例对照。
- 分析基线280种生物标志物,用Wilcoxon秩和检验比较组间分布,用稀疏贝叶斯回归模型筛选潜在VTE生物标志物联合面板。
主要发现
- 伴与不伴VTE的癌症患者基线分布差异最大的标志物包括SDF-1、TSH和单核细胞趋化蛋白4降低,生长激素和IL-1R1升高。
- 生存者与死亡者之间显著不同的标志物包括ST2、IL-8和C反应蛋白。
- 回归分析还识别出SDF-1和TSH降低。
- 通路分析显示细胞因子和趋化因子活性富集,IL-1R1、SDF-1和GH为VTE或死亡的最强预测因子。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer is associated with an increased risk of venous thromboembolism (VTE). In the CASSINI study, ambulatory cancer patients with a Khorana risk score ≥2 had a reduced risk of VTE while receiving rivaroxaban. This analysis used blood samples from CASSINI to compare biomarker levels between patients with and without VTE. VTE occurred in 62 patients during the 6 months of CASSINI (cases), and they were matched by age, sex, cancer type, tumor stage, and Khorana score to 62 controls. Baseline blood samples were analyzed for 280 biomarkers, and biomarker distribution was compared using the Wilcoxon rank-sum test between groups defined by VTE occurrence and vital status. Sparse Bayesian regression modeling was used to select a joint panel of potential VTE biomarkers. Biomarkers with the largest differences in baseline distribution among cancer patients with and without VTE included decreases in stromal cell-derived factor-1 (SDF-1), thyroid-stimulating hormone (TSH), and monocyte chemotactic protein 4 and increases in growth hormone (GH) and interleukin-1 receptor type 1 (IL-1R1). Between survivors and those who died, significantly different biomarkers included ST2, IL-8, and C-reactive protein. Regression analyses also identified decreases in SDF-1 and TSH. Pathway analysis indicated enrichment of cytokine and chemokine activity with IL-1R1, SDF-1, and GH, which are the strongest predictors of VTE or death. Our analyses highlight the interactions between hemostatic and inflammatory processes and identify candidate biomarkers of cancer-associated VTE. Prospective studies will determine clinical relevance of these biomarkers. This trial was registered at www.ClinicalTrials.gov as #NCT02555878.
引用
- Khorana AA, Barnard J, Wun T, et al. Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI. Blood Adv. 2022. PMID: 34807979. doi:10.1182/bloodadvances.2021005710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。